Literature DB >> 10222418

Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion.

M Bredel1, I F Pollack, J M Freund, J Rusnak, J S Lazo.   

Abstract

Recent studies in our laboratory have shown that UCN-01 (7-hydroxystaurosporine), which is a derivative of the non-selective protein kinase inhibitor staurosporine that exhibits relative selectivity for protein kinase C (PKC), is a potent inhibitor of glioma growth in in vitro and in vivo models. This agent exhibits both cytotoxic and cytostatic effects, depending on the time period of drug exposure. In the present study, we examined whether UCN-01-induced cytotoxicity correlated with the induction of apoptosis, and characterized further the time course of this process as a prelude to application of UCN-01 in clinical trials. We first demonstrated that the cytotoxic effects of UCN-01 were associated with the induction of morphological features of apoptosis. Secondly, we identified electrophoretic features of apoptosis semiquantitatively at a series of time points using field inversion gel electrophoresis. These studies showed a peak in the induction of high-molecular-weight DNA fragmentation after 3-6 days of drug treatment. Thirdly, we measured the percentage of cells undergoing apoptosis at various time points using a terminal transferase-catalyzed in situ end-labeling technique, which confirmed a time- and concentration-dependent increase in apoptotic cell numbers. This correlated with a progressive decrease in the percentage of cells that were viable as assessed by trypan blue exclusion. Cell killing peaked within 2-4 days after beginning UCN-01 treatment, but continued at a lower level in the ensuing days. Taken together, these studies demonstrated that extended periods of exposure to UCN-01 are needed for optimal manifestation of cytotoxic effects against glioma cells, a factor that must be taken into consideration in the design of future clinical trials with this agent for malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10222418     DOI: 10.1023/a:1006047025425

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  54 in total

1.  Programmed Cell Death (Apoptosis) and Cancer Chemotherapy.

Authors: 
Journal:  Cancer Control       Date:  1996-07       Impact factor: 3.302

2.  Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways.

Authors:  I F Pollack; M S Randall; M P Kristofik; R H Kelly; R G Selker; F T Vertosick
Journal:  J Neurosurg       Date:  1991-08       Impact factor: 5.115

3.  Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C.

Authors:  W D Jarvis; A J Turner; L F Povirk; R S Traylor; S Grant
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

4.  Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.

Authors:  J M Rusnak; T P Calmels; D G Hoyt; Y Kondo; J C Yalowich; J S Lazo
Journal:  Mol Pharmacol       Date:  1996-02       Impact factor: 4.436

5.  Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro.

Authors:  I F Pollack; M S Randall; M P Kristofik; R H Kelly; R G Selker; F T Vertosick
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

6.  Protein kinase C and growth regulation in malignant gliomas.

Authors:  W T Couldwell; D R Hinton; R E Law
Journal:  Neurosurgery       Date:  1994-12       Impact factor: 4.654

7.  Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C.

Authors:  W T Couldwell; J P Antel; V W Yong
Journal:  Neurosurgery       Date:  1992-10       Impact factor: 4.654

8.  The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors.

Authors:  I F Pollack; S Kawecki
Journal:  Pediatr Neurosurg       Date:  1995       Impact factor: 1.162

Review 9.  Protein kinase C and growth regulation of malignant gliomas.

Authors:  G H Baltuch; N P Dooley; J G Villemure; V W Yong
Journal:  Can J Neurol Sci       Date:  1995-11       Impact factor: 2.104

10.  Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity.

Authors:  D L Hill; K F Tillery; L M Rose; C F Posey
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more
  6 in total

1.  PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.

Authors:  Crissy Dudgeon; Peng Wang; Xiameng Sun; Rui Peng; Quanhong Sun; Jian Yu; Lin Zhang
Journal:  Mol Cancer Ther       Date:  2010-10-26       Impact factor: 6.261

2.  Enzastaurin induces H2AX phosphorylation to regulate apoptosis via MAPK signalling in malignant glioma cells.

Authors:  Esther P Jane; Ian F Pollack
Journal:  Eur J Cancer       Date:  2009-11-11       Impact factor: 9.162

3.  Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.

Authors:  Antonio Jimeno; Michelle A Rudek; Thomas Purcell; Daniel A Laheru; Wells A Messersmith; Janet Dancey; Michael A Carducci; Sharyn D Baker; Manuel Hidalgo; Ross C Donehower
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-12       Impact factor: 3.333

4.  A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.

Authors:  Paula M Fracasso; Kerry J Williams; Ronald C Chen; Joel Picus; Cynthia X Ma; Matthew J Ellis; Benjamin R Tan; Timothy J Pluard; Douglas R Adkins; Michael J Naughton; Janet S Rader; Matthew A Arquette; James W Fleshman; Allison N Creekmore; Sherry A Goodner; Lisa P Wright; Zhanfang Guo; Christine E Ryan; Yu Tao; Eliane M Soares; Shi-Rong Cai; Li Lin; Janet Dancey; Michelle A Rudek; Howard L McLeod; Helen Piwnica-Worms
Journal:  Cancer Chemother Pharmacol       Date:  2010-08-08       Impact factor: 3.333

Review 5.  Targeting Cell Cycle Checkpoint Kinases to Overcome Intrinsic Radioresistance in Brain Tumor Cells.

Authors:  Tijana Vlatkovic; Marlon R Veldwijk; Frank A Giordano; Carsten Herskind
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

6.  Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.

Authors:  M Signore; F Pelacchi; S di Martino; D Runci; M Biffoni; S Giannetti; L Morgante; M De Majo; E F Petricoin; L Stancato; L M Larocca; R De Maria; R Pallini; L Ricci-Vitiani
Journal:  Cell Death Dis       Date:  2014-05-08       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.